Histone deacetylase inhibitors: A survey of recent patents

Expert Opinion on Therapeutic Patents

Volumn 15, Issue 12, 2005, Pages 1677-1690

  Weinmann, Hilmar ^a   Ottow, Eckhard ^b  

^a BAYER PHARMA AG   (Germany)

^b NONE

Author keywords

Benzamide; Cancer treatment; Cyclic peptide; Histone deacetylase (HDAC) inhibitor; Hydroxamic acid

Indexed keywords

4 [N (2 HYDROXYETHYL) N [2 (3 INDOLYL)ETHYL]AMINOMETHYL]CINNAMOHYDROXAMIC ACID; 4 N ACETYLDINALINE; 6 (1,3 DIOXO 1H,3H BENZO[DE]ISOQUINOLIN 2 YL) N HYDROXYHEXANAMIDE; ARYLBUTYRIC ACID DERIVATIVE; BENZIMIDAZOLE; BENZOTHIOPHENE; BUTYRIC ACID; CARBANILAMIDE DERIVATIVE; CARBOLINE DERIVATIVE; CARBONYL DERIVATIVE; CYCLOPEPTIDE; DNA TOPOISOMERASE; DNA TOPOISOMERASE INHIBITOR; FK 288; HISTONE ACETYLTRANSFERASE; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; HISTONE H3; HISTONE H4; HYDROXAMIC ACID DERIVATIVE; IMIDAZOLE DERIVATIVE; N (2 AMINOPHENYL) 4 (3 PYRIDINYLMETHOXYCARBONYLAMINOMETHYL)BENZAMIDE; OXAMFLATIN; SHORT CHAIN FATTY ACID; THIOPHENE; TRICHOSTATIN A; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALPROIC ACID; VORINOSTAT; ZINC;

ACUTE GRANULOCYTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; ATOPIC DERMATITIS; AUTOIMMUNE DISEASE; BLADDER CARCINOMA; CANCER CHEMOTHERAPY; CANCER GROWTH; CLINICAL TRIAL; CYTOTOXICITY; DRUG DOSE REGIMEN; DRUG INDUSTRY; DRUG MECHANISM; DRUG RESEARCH; DRUG SAFETY; DRUG STRUCTURE; DRUG TARGETING; GENE TARGETING; GRAFT REJECTION; GROWTH INHIBITION; HEPATITIS C; HUMAN; NONHUMAN; PATENT; PSORIASIS; REVIEW; RHEUMATOID ARTHRITIS; STRUCTURE ANALYSIS;

EID: 30344440073     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.15.12.1677     Document Type: Review

References (48)

1. MILLER TA: Patent status of histone deacetylase inhibitors. Expert Opin. Ther. Patents (2004) 14(6):791-804.
2. GREENLEE RT, MURRAY T, BOLDEN S, WINGO PA: Cancer Statistics 2000. CA Cancer J. Clin. (2000) 50:7-33.
3. MAI A, MASSA A, ROTILI D et al.: Histone deacetylation in epigenetics: an attractive target for anticancer therapy. Med. Res. Rev. (2005) 25:261-309.
4. MCLAUGHLIN F, LA THANGUE N: Histone deacetylase inhibitors open new doors in cancer therapy. Biochem. Pharmacol. (2004) 68:1139-1144.
5. MEI S, HO AD, MAHLKNECHT U: Role of histone deacetylase inhibitors in the treatment of cancer. Int. J. Oncol. (2004) 25:1509-1519.
6. BHALLA KN: Epigenetic and chromatin modifiers as targeted therapy of hematologic malignancies. J. Clin. Oncol. (2005) 23(17):3971-3993.
7. ROSATO R, GRANT S: Histone deacetylase inhibitors in clinical development. Expert Opin. Investig. Drugs (2004) 13:21-38.
8. MARKS PA, RICHON VM, BRESLOW R, RIFKIND RA: Histone deacetylase inhibitors as new cancer drugs. Curr. Opin. Oncol. (2001) 13:477-483.
9. KELLY WK, O'CONNOR OA, MARKS PA: Histone deacetylase inhibitors: from target to clinical trial. Expert Opin. Investig. Drugs (2002) 11:1695-1713.
10. HESS-STUMPP H: Histone deacetylase inhibitors and cancer: from cell biology to the clinic. Eur. J. Cell Biol. (2005) 84:109-121.
11. DRUMMOND DC, NOBLE CO, KIRPOTIN DB et al.: Clinical development of histone deacetylase inhibitors as anticancer agents. Ann. Rev. Pharmacol. Toxicol. (2005) 45:495-528.
12. PIEKARTZ R, BATES S: A review of depsipeptide and other histone deacetylase inhibitors in clinical trials. Curr. Pharm. Des. (2004) 10(19):2289-2298.
13. DE RUIJTER AJ, VAN GENNIP AH, CARON HN, KEMP S, VAN KUILENBURG AB: Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem. J. (2003) 370-737-749.
14. GRAY GG, EKSTROM TJ: The human histone deacetylase family. Exp. Cell. Res. (2001) 262:75-83.
15. HAGGARTY SJ, KOELLER KM, WONG JC, GROZINGER CM, SCHREIBER SL: Domain-selective small molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation. Prac. Natl. Acad. Sci. USA (2003) 100(8):4389-4394.
16. BALI P, PRANPAT M, BRADNER J et al.: Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors. J. Biol. Chem. (2005) 280(29):6729-6734.
17. GAO L, CUETO MA, ASSELBERGS F, ATAOJA P: Cloning and functional characterization of HDAC11, a novel member of the human histone deacetylase family. J. Biol. Chem. (2002) 277:25748-25755.
18. FINNIN MS, DONIGIAN JR, COHEN A et al.: Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature (1999) 401:188-193.
19. SOMOZA JR, SKENE RJ, KATZ BA et al.: Structural snapshots of human HDAC8 provide insights into the Class I histone deacetylases, Structure (2004) 12:1325-1334.
20. VANNINI A, VOLPARI C, FILOCAMO G et al.: Crystal structure of a eukaryotic zinc-dependent histone deacetylase, human HDAC8, complexed with a hydroxamic acid inhibitor. Proc. Natl. Acad. Sci. USA (2004) 101:15064-15069.
21. YOSHIDA M, MATSUYAMA A, KOMATSU Y, NISHINO N: From discovery to the coming generation of histone deacetylase inhibitors. Curr. Med. Chem. (2003) 10:2351-2358.
22. MONNERET C: Histone deacetylase inhibitors. Eur. J. Med. Chem. (2005) 40:1-13.
23. MILLER TA, WITTER DJ, BELVEDERE S: Histone deacetylase inhibitors. J. Med. Chem. (2003) 46:5097-5116.
24. GOMEZ-VIDAL JA, CAMPOS J, MARCHAL JA et al.: Actual targets in cytodifferentiation cancer therapy. Curr. Topics Med. Chem. (2004) 4:175-202.
25. REMISZEWSKI SW: Recent advances in the discovery of small molecule histone deacetylase inhibitors. Curr. Opin. Drug Disc. Dev. (2002) 5:487-99.
26. MARKS PA, MILLER T, RICHON VM: Histone deacetylases. Curr. Opin. Pharmacol. (2003) 3:344-351.
27. WEINMANN H, OTTOW E: Recent advances in medicinal chemistry of histone deacetylase inhibitors. Ann. Rep. Med. Chem. (2004) 39:186-196.
28. YANG K, LOU B: Molecular diversity of hydroxamic acids: part I. Solution- and solid-phase synthesis. Mini Rev. Med. Chem. (2003) 3:349-360.
29. LOU B, YANG K: Molecular diversity of hydroxamic acids: part II. Potential therapeutic applications. Mini Rev. Med. Chem. (2003) 3:609-620.
30. CURTIN ML: Synthesis of novel hydroxamate and non-hydroxamate histone deacetylase inhibitors. Curr. Opin. Drug Discov. Devel. (2004) 7: 848-868.
31. SHABBEER S, CARDUCCI MA: Focus on deacetylation for therapeutic benefit. Investig. Drugs (2005) 8:144-154.
32. KELLY WK, CONNOR OA, KRUG L, CHIAO J, HEANEY M, CURLEY T: Phase I study of the oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), in patients with advanced cancer. J. Clin. Oncol. (2005) 23(17).3923-3931.
33. KELLY WK, MARKS PA: Drug insight: histone deacetylase inhibitors - development of the new targeted anticancer agent suberoylanilide hydroxamic acid. Nat. Clin. Pract. Oncol. (2005) 2(3):150-157.
34. ATADJA P, GAO L, KWON P et al.: Selective growth inhibition of tumor cells by a novel histone deacetylase inhibitor, NVP-LAQ824. Cancer Res. (2004) 64:689-695.
35. PLUMB JA, FINN PW, WILLIAMS RJ et al.: Pharmacodynamic response and inhibition of growth of human tumor xenografts by the novel histone deacetylase inhibitor PXD101. Mol. Cancer Ther. (2003) 2:721-728.
36. VANHAECKE T, PAPELEU P, ELAUT G, ROGIERS V: Trichostatin A - like hydroxamate histone deacetylase inhibitors as therapeutic agents: toxicological point of view. Curr. Med. Chem. (2004) 11:1629-1643.
37. FREY RR, WADA CK, GARLAND RB et al.: Trifluoromethyl ketones as inhibitors of histone deacetylase. Bioarg. Med. Chem. Lett. (2002) 12:3443-3447.
38. SUZUKI T, MATSUURA A, KOUKETSU A, NAKAGAWA H, MIYATA N: Identification of a potent non-hydroxamate histone deacetylase inhibitor by mechanism-based drug design. Bioorg. Med. Chem. Lett. (2005) 15:331-335.
39. CHEN B, PETUKHOV PA, JUNG M et al.: Chemistry and biology of mercaptoacetamides as novel histone deacetylase inhibitors. Bioorg. Med. Chem. Lett. (2005) 15:1389-1392.
40. NEWMARK HL, LUPTON JR, YOUNG CW: Butyrate as a differentiating agent: pharmacokinetics, analogues and current status. Cancer Lett. (2001) 78:1-5.
41. DIGIUSEPPE JA, WENIG LJ, YU KH et al.: Phenylbutyrate-induced G1 arrest and apoptosis in myeloid leukemia cells: structure-function analysis. Leukemia (1999) 13:1243-1253.
42. GÖTTLICHER M, MINUCCI S, ZHU P et al.: Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J. (2001) 20:6969-6978.
43. LU Q, WANG D-S, CHEN C-S, HU Y-D, CHEN C-S: Structure-based optimization of phenylbutyratederived histone deacetylase inhibitors. J. Med. Chem. (2005) 48:5530-5535.
44. SUZUKI T, ANDO T, TSUCHIYA K, FUKAZAWA N, SAITO A: Synthesis and histone deacetylase inhibitory activity of new benzamide derivatives. J. Med. Chem. (1999) 42:3001-3003.
45. MCLAUGHLIN F, LA THANGUE NB: Histone deacetylase inhibitors in psoriasis therapy. Curr. Drug Targets Inflamm. Allergy (2004) 3:213-219.
46. ARTS J, DE SCHEPER S, VAN EMELEN K: Histone deacetylase inhibitors: from chromatin remodeling to experimental cancer therapeutics. Curr. Med. Chem. (2003) 10:2343-2350.
47. BERTOS NR, WANG AH, YANG XJ: Class II histone deacetylases: structure, function, and regulation. Biochem. Cell. Biol. (2001) 79:243-252.
48. UNGERSTEDT JS, SOWA Y, XU WS et al.: Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors. Proc. Natl. Acad. Sci. USA (2005) 102(3):673-678.